Rhythm Pharmaceuticals

Price —

Potential 0 Risk 0

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Nothing yet

News Page 1 of 1

A R S

Analysts Piper Sandler upgrade Rivian (RIVN) and Mobileye (MBLY) to Overweight, citing strong demand outlooks

07/27/2026, 05:36 AM investing rating_growth Analysts: analysts, Piper Sandler Aduro Clean Technologies Rhythm Pharmaceuticals Sonida Senior Living Ford Motor Company Rivian Anheuser-Busch InBev Cameco Mobileye Global Williams-Sonoma General Motors

Recent analyst upgrades and initiations across various sectors indicate a positive outlook for several companies, including Rivian, Mobileye, and Williams-Sonoma, suggesting potential investment opportunities for investors.